Rexahn Pharmaceuticals Inc (RNN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Rexahn Pharmaceuticals Inc (Rexahn Pharmaceuticals), formerly Corporate Road Show.com Inc is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of cancer. The company develops anti-cancer drug candidates including Archexin that is intended for the treatment of pancreatic cancer. It develops RX-3117 used for the treatment of pancreatic, bladder, colon, and lung cancer. The company also offers Supinoxin for solid tumors. It provides pre-clinical development of products intended for the treatment of tumors. The company partners with other pharmaceutical companies for oncology product development. Rexahn Pharmaceuticals is headquartered in Rockville, Maryland, the US.

Rexahn Pharmaceuticals Inc (RNN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Zhejiang Haichang Biotechnology Enters into Licensing Agreement with Rexahn Pharma 11
Rexahn Pharma Enters Into Licensing Agreement With University of Maryland For Nano-Polymer-Drug Conjugate Systems 12
Rexahn Pharma Enters Into Licensing Agreement With Ohio State Innovation Foundation For Oligonucleotide Drug Delivery Platform 13
Equity Offering 14
Rexahn Pharma Raises USD8 Million in Private Placement of Units 14
Rexahn Pharma Raises USD10 Million in Private Placement of Shares and Warrants 16
Rexahn Pharma Raises USD6 Million in Private Placement of Shares and Warrants 17
Rexahn Pharma Raises USD5 Million in Private Placement of Units 18
Rexahn Pharma to Raise up to USD7 Million in Private Placement of Units 20
Rexahn Pharma Completes Private Placement Of Units For US$20 Million 21
Rexahn Pharma Completes Private Placement Of Units For US$5.3 Million 22
Rexahn Pharma Completes Public Offering Of Units For US$5.7 Million 23
Rexahn Pharma Completes Public Offering Of Common Stock For US$6.6 Million 24
Acquisition 26
Pfizer Rumored To Acquire Rexahn Pharma 26
Rexahn Pharmaceuticals Inc - Key Competitors 27
Rexahn Pharmaceuticals Inc - Key Employees 28
Rexahn Pharmaceuticals Inc - Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
May 07, 2018: Rexahn Announces First Quarter 2018 Financial Results 30
Mar 12, 2018: Rexahn Pharmaceuticals Announces Full Year 2017 Financial Results 31
Nov 06, 2017: Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33
Aug 07, 2017: Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results 35
May 04, 2017: Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 37
Feb 27, 2017: Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update 39
Corporate Communications 41
Jan 04, 2018: Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer 41
Sep 01, 2017: Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors 42
Clinical Trials 43
Jun 04, 2017: Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology 2017 Annual Meeting 43
May 08, 2017: Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting 45
Jan 20, 2017: Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium 46
Other Significant Developments 48
Aug 14, 2017: Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List Of Tables

List of Tables
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rexahn Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zhejiang Haichang Biotechnology Enters into Licensing Agreement with Rexahn Pharma 11
Rexahn Pharma Enters Into Licensing Agreement With University of Maryland For Nano-Polymer-Drug Conjugate Systems 12
Rexahn Pharma Enters Into Licensing Agreement With Ohio State Innovation Foundation For Oligonucleotide Drug Delivery Platform 13
Rexahn Pharma Raises USD8 Million in Private Placement of Units 14
Rexahn Pharma Raises USD10 Million in Private Placement of Shares and Warrants 16
Rexahn Pharma Raises USD6 Million in Private Placement of Shares and Warrants 17
Rexahn Pharma Raises USD5 Million in Private Placement of Units 18
Rexahn Pharma to Raise up to USD7 Million in Private Placement of Units 20
Rexahn Pharma Completes Private Placement Of Units For US$20 Million 21
Rexahn Pharma Completes Private Placement Of Units For US$5.3 Million 22
Rexahn Pharma Completes Public Offering Of Units For US$5.7 Million 23
Rexahn Pharma Completes Public Offering Of Common Stock For US$6.6 Million 24
Pfizer Rumored To Acquire Rexahn Pharma 26
Rexahn Pharmaceuticals Inc, Key Competitors 27
Rexahn Pharmaceuticals Inc, Key Employees 28

List Of Figures

List of Figures
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Rexahn Pharmaceuticals Inc - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Rexahn Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Rexahn Pharmaceuticals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350 View Report

Rexahn Pharmaceuticals Inc (RNN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Rexahn Pharmaceuticals Inc (Rexahn Pharmaceuticals), formerly Corporate Road Show.com Inc is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of cancer. The company develops anti-cancer drug candidates

USD 250 View Report

EyePoint Pharmaceuticals Inc (PSDV) - Product Pipeline Analysis, 2019 Update

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert

USD 750 View Report

RespireRx Pharmaceuticals Inc (RSPI) - Strategic SWOT Analysis Review

RespireRx Pharmaceuticals Inc (RSPI) - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis,

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available